Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Biodistribution, Dosimetry of 68Ga-NYM215 PET/CT and Head-to-head Comparison With 68Ga-DOTATATE PET/CT in Patients With Neuroendocrine Neoplasms: A Prospective Study

NCT07835906 is registered in ClinicalTrials.gov with Peking Union Medical College Hospital as lead sponsor.

NCT NCT07835906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07835906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Biodistribution, Dosimetry of 68Ga-NYM215 PET/CT and Head-to-head Comparison With 68Ga-DOTATATE PET/CT in Patients With Neuroendocrine Neoplasms: A Prospective Study
Lead sponsor
Peking Union Medical College Hospital
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 10, 2026
Completion date
October 20, 2027
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine neoplasms